Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIPASTIN: Cisplatin HCIP and Bevacizumab in Ovarian, Fallopian Tube, or Primary Peritoneal Adenocarcinoma
NCT02217956Phase 1Completed
- Sponsor
- Gustave Roussy
- Start
- Jun 2011
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin in Malignant Ovarian Tumor, fallopian tube adenocarcinoma and primary peritoneal carcinoma (PPC), sponsored by Gustave Roussy. Primary endpoint: Toxicity. Started Jun 2011; status: completed.
02
Drugs
cisplatin
03
Conditions
Malignant Ovarian Tumorfallopian tube adenocarcinomaprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02217956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217956.